Please login to the form below

oncolytic viruses

This page shows the latest oncolytic viruses news and features for those working in and with pharma, biotech and healthcare.

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

These trials are designed to investigate Libtayo across a range of settings, monotherapy and in combination with chemotherapy and novel agents including vaccines, oncolytic viruses and bispecific antibodies and others.

Latest news

AZ invests more in IO with Transgene oncolytic virus deal

AstraZeneca has similar plans to combined Transgene’s oncolytic viruses withits in-house pipeline ofImmuno-oncology (IO) treatments. ... AstraZeneca's Jean-Charles Soria. Jean-Charles Soria, AstraZeneca’s senior vice president, Oncology R&D, said:
Catalent preps for complex therapy boom with $1.2bn Paragon buy

Paragon, which is backed by private-equity firms Camden Partners and NewSpring Capital, helps its clients develop and produce gene therapies, next-generation vaccines, and other complex biopharmaceuticals such as oncolytic ... viruses and CAR-T cell
Boehringer bolts on another immuno-oncology company

The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from ... 2006. Other oncolytic virus candidates
Vyriad inks immunotherapy alliance with Merck/Pfizer

Oncolytic viruses are engineered to selectively replicate within and destroy cancer cells while simultaneously augmenting anti-tumour immunity, and are generally injected directly into tumour sites. ... There’s a lot of activity going on in R&D however,
J&J pays $140m upfront for cancer-busting virus firm BeneVir

that the promise of oncolytic viruses will come to fruition when they are used in combination with other cancer immunotherapies. ... The biotech’s website indicates that its oncolytic viruses lend themselves to co-administration with immune checkpoint

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

cell-based therapies and oncolytic viruses that attack malignant cells directly, and cancer vaccines that try to kickstart an intrinsic immune reaction to the tumour. ... Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and
Gene therapy

From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA. ... In contrast, viruses still
Deal Watch December 2016

995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “armed” oncolytic virus targeting tumour cells. ... technology in the development of immunomodulatory oncolytic viruses.
The Maverick: giving medicines away free

His fundamental idea is to create synthetic viruses that can invade cancer cells, destroy them, and then multiply into more viruses to kill the remaining cancerous cells. ... This forms part of a new research area known as oncolytic virology that uses

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Turnstone Biologics bolsters leadership team

Oncolytic viruses and cancer vaccines have the potential to benefits a wide range of patients living with cancer, and the company’s proprietary viral platform technology is at the forefront of ... we advance clinical development of our next-generation

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Products as portfolios: positioning immuno-oncology products

In addition, developments in oncolytic viruses mean the options for patients with certain solid tumours are ever-expanding.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...